Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Emily K. Larsen"'
Autor:
Dirk Huebner, Emily K. Larsen, Scott E. Smith, Joseph D. Rosenblatt, Stephen M. Ansell, Joseph M. Connors, Ajay K. Gopal, Anas Younes, Kerry J. Savage, Robert T. Chen, Abraham P. Fong, Andreas Engert
Publikováno v:
Blood. 128:1562-1566
Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed hematopoietic autologous stem cell transplantation. At 5 years, the
Autor:
Andy I. Chen, Eric L. Sievers, Patrick J. Stiff, Tamas Masszi, Andy Chi, Dirk Huebner, Jerzy Holowiecki, Angelo Michele Carella, Craig H. Moskowitz, Emily K. Larsen, Dzhelil Osmanov, Edward Agura, Veronika Bachanova, Auayporn Nademanee, Jan Walewski, John W. Sweetenham, Alessandro M. Gianni, Naomi N. H. Hunder, Anna Sureda, Muneer H. Abidi
Publikováno v:
The Lancet. 385:1853-1862
High-dose therapy followed by autologous stem-cell transplantation is standard of care for patients with relapsed or primary refractory Hodgkin's lymphoma. Roughly 50% of patients might be cured after autologous stem-cell transplantation; however, mo
Autor:
Emily K. Larsen, Anas Younes, Ajay K. Gopal, Eric L. Sievers, Joseph M. Connors, Andreas Engert, Andrei R. Shustov, Barbara Pro, Dana A. Kennedy, Xuedong Chi
Background: Independent central review of clinical imaging remains the standard for oncology clinical trials with registration potential. A limited independent central review strategy has been proposed for solid tumor trials based on concordance betw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4db6f8a44d2ec67f8329f3a190e414b3
https://europepmc.org/articles/PMC5572138/
https://europepmc.org/articles/PMC5572138/
Autor:
Eric L. Sievers, Joseph M. Connors, Joseph D. Rosenblatt, Andreas Engert, Emily K. Larsen, Scott E. Smith, Kerry J. Savage, Robert T. Chen, Stephen M. Ansell, Xuedong Chi, Ajay K. Gopal, Anas Younes
We present response and survival outcomes of a pivotal phase 2 trial of the antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant (N = 102) after a median observati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f35e5f2d358d548f3b29b825e57e89e3
https://europepmc.org/articles/PMC4335079/
https://europepmc.org/articles/PMC4335079/
Autor:
Ramón García-Sanz, Juan Pinelli, Angelo Michele Carella, Amanda F. Cashen, Veronika Bachanova, Jeffrey Matous, Andy I. Chen, Auayporn Nadamanee, Dirk Huebner, Sally Arai, Edward Agura, Emily K. Larsen
Publikováno v:
Biology of Blood and Marrow Transplantation. 23:S46
Autor:
Muneer H. Abidi, Andy I. Chen, Tamas Masszi, Auayporn Nadamanee, Veronika Bachanova, Naomi N. H. Hunder, Patrick J. Stiff, Simonetta Viviani, Anna Sureda, Angelo Michele Carella, Dirk Huebner, Jan Walewski, Emily K. Larsen, Jerzy Holowiecki, Craig H. Moskowitz, Dzhelil Osmanov, John W. Sweetenham, Edward Agura
Publikováno v:
Blood. 126:3172-3172
Introduction The AETHERA trial is a phase 3, randomized, placebo-controlled trial (ClinicalTrials.gov #NCT01100502), which evaluated whether post-ASCT consolidation treatment with brentuximab vedotin (BV) could prevent disease progression in Hodgkin
Autor:
Joseph D. Rosenblatt, Ajay K. Gopal, Stephen M. Ansell, Robert T. Chen, Dirk Huebner, Emily K. Larsen, Joseph M. Connors, Anas Younes, Scott E. Smith, Andreas Engert, Kerry J. Savage, Abraham P. Fong
Publikováno v:
Blood. 126:2736-2736
Background: Classical Hodgkin lymphoma (HL) is characterized by the presence of CD30-positive Hodgkin Reed-Sternberg cells. The standard of care for patients (pts) with relapsed or refractory (R/R) HL is salvage chemotherapy followed by high dose che
Publikováno v:
The FASEB Journal. 21
Autor:
Emily K. Larsen, Naomi N. H. Hunder, Jerzy Holowiecki, Simonetta Viviani, Auayporn Nademanee, Jan Walewski, John W. Sweetenham, Shih-Yuan Lee, Tamas Masszi, Veronika Bachanova, Muneer H. Abidi, Patrick J. Stiff, Craig H. Moskowitz, Andy I. Chen, Dirk Huebner
Publikováno v:
Journal of Clinical Oncology. 33:8519-8519
8519 Background: In the phase III, randomized, placebo-controlled AETHERA trial, PFS was significantly improved with brentuximab vedotin (BV) vs placebo (HR=0·57, P=0·001) in HL pts at risk of prog...
Autor:
Dirk Huebner, Craig H. Moskowitz, Patrick J. Stiff, Jerzy Holowiecki, Andy I. Chen, Dzhelil Osmanov, Auayporn Nadamanee, Veronika Bachanova, Tamas Masszi, Emily K. Larsen, Muneer H. Abidi, John W. Sweetenham, Naomi N. H. Hunder, Anna Sureda, Jan Walewski, Alessandro M. Gianni, Angelo Michele Carella, Edward Agura
Publikováno v:
Blood. 124:673-673
Background For the past 20 years, high-dose therapy plus autologous stem cell transplant (ASCT) has been the standard of care for patients (pts) with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), providing a cure for approximately 50% of